Stockholders' Equity Attributable to Parent of PharmaCyte Biotech, Inc. from 30 Apr 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
PharmaCyte Biotech, Inc. quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 30 Apr 2010 to 31 Oct 2025.
  • PharmaCyte Biotech, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 31 Oct 2025 was $35,235,089, a 19% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

PharmaCyte Biotech, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $35,235,089 -$8,216,057 -19% 31 Oct 2025 10-Q 18 Dec 2025 2026 Q2
Q2 2025 $43,591,588 -$4,116,782 -8.6% 31 Jul 2025 10-Q 18 Dec 2025 2026 Q2
Q1 2025 $51,891,069 +$24,243,466 +88% 30 Apr 2025 10-Q 18 Dec 2025 2026 Q2
Q4 2024 $40,250,185 +$8,875,226 +28% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $43,451,146 +$6,683,638 +18% 31 Oct 2024 10-Q 18 Dec 2025 2026 Q2
Q2 2024 $47,708,370 +$8,514,581 +22% 31 Jul 2024 10-Q 18 Dec 2025 2026 Q2
Q1 2024 $27,647,603 -$45,042,741 -62% 30 Apr 2024 10-Q 18 Dec 2025 2026 Q2
Q4 2023 $31,374,959 -$45,747,741 -59% 31 Jan 2024 10-Q 17 Mar 2025 2025 Q3
Q3 2023 $36,767,508 -$44,270,064 -55% 31 Oct 2023 10-Q 17 Mar 2025 2025 Q3
Q2 2023 $39,193,789 -$47,101,925 -55% 31 Jul 2023 10-Q 17 Mar 2025 2025 Q3
Q1 2023 $72,690,344 -$17,229,422 -19% 30 Apr 2023 10-K 11 Aug 2025 2025 FY
Q4 2022 $77,122,700 -$14,207,490 -16% 31 Jan 2023 10-Q 18 Mar 2024 2024 Q3
Q3 2022 $81,037,572 -$11,086,025 -12% 31 Oct 2022 10-Q 18 Mar 2024 2024 Q3
Q2 2022 $86,295,714 +$80,583,332 +1411% 31 Jul 2022 10-Q 18 Mar 2024 2024 Q3
Q1 2022 $89,919,766 +$83,240,315 +1246% 30 Apr 2022 10-K 13 Aug 2024 2024 FY
Q4 2021 $91,330,190 +$83,717,217 +1100% 31 Jan 2022 10-Q 16 Mar 2023 2023 Q3
Q3 2021 $92,123,597 +$83,846,978 +1013% 31 Oct 2021 10-Q 16 Mar 2023 2023 Q3
Q2 2021 $5,712,382 -$532,893 -8.5% 31 Jul 2021 10-Q 16 Mar 2023 2023 Q3
Q1 2021 $6,679,451 +$1,590,493 +31% 30 Apr 2021 10-K 31 Jul 2023 2023 FY
Q4 2020 $7,612,973 +$3,293,641 +76% 31 Jan 2021 10-Q 15 Mar 2022 2022 Q3
Q3 2020 $8,276,619 +$3,742,142 +83% 31 Oct 2020 10-Q 15 Mar 2022 2022 Q3
Q2 2020 $6,245,275 +$1,245,800 +25% 31 Jul 2020 10-Q 15 Mar 2022 2022 Q3
Q1 2020 $5,088,958 +$49,413 +0.98% 30 Apr 2020 10-K 28 Jul 2022 2022 FY
Q4 2019 $4,319,332 -$1,046,363 -20% 31 Jan 2020 10-Q 12 Mar 2021 2021 Q3
Q3 2019 $4,534,477 -$869,727 -16% 31 Oct 2019 10-Q 12 Mar 2021 2021 Q3
Q2 2019 $4,999,475 -$1,198,673 -19% 31 Jul 2019 10-Q 12 Mar 2021 2021 Q3
Q1 2019 $5,039,545 -$729,144 -13% 30 Apr 2019 10-K 10 Aug 2021 2021 FY
Q4 2018 $5,365,695 -$472,382 -8.1% 31 Jan 2019 10-Q 13 Mar 2020 2020 Q3
Q3 2018 $5,404,204 -$1,944,205 -26% 31 Oct 2018 10-Q 13 Mar 2020 2020 Q3
Q2 2018 $6,198,148 -$2,461,167 -28% 31 Jul 2018 10-Q 13 Mar 2020 2020 Q3
Q1 2018 $5,768,689 -$2,318,558 -29% 30 Apr 2018 10-K 13 Aug 2020 2020 FY
Q4 2017 $5,838,077 -$1,198,599 -17% 31 Jan 2018 10-Q 14 Mar 2019 2019 Q3
Q3 2017 $7,348,409 +$1,065,685 +17% 31 Oct 2017 10-Q 14 Mar 2019 2019 Q3
Q2 2017 $8,659,315 +$1,592,133 +23% 31 Jul 2017 10-Q 14 Mar 2019 2019 Q3
Q1 2017 $8,087,247 +$1,564,561 +24% 30 Apr 2017 10-K 13 Aug 2019 2019 FY
Q4 2016 $7,036,676 +$100,247 +1.4% 31 Jan 2017 10-Q 13 Mar 2017 2017 Q3
Q3 2016 $6,282,724 -$614,810 -8.9% 31 Oct 2016 10-Q 02 Dec 2016 2017 Q2
Q2 2016 $7,067,182 -$761,514 -9.7% 31 Jul 2016 10-Q 06 Sep 2016 2017 Q1
Q1 2016 $6,522,686 -$1,254,440 -16% 30 Apr 2016 10-K 20 Jul 2018 2018 FY
Q4 2015 $6,936,429 +$688,470 +11% 31 Jan 2016 10-Q 08 Mar 2016 2016 Q3
Q3 2015 $6,897,534 +$515,307 +8.1% 31 Oct 2015 10-Q/A 19 Jan 2016 2016 Q2
Q2 2015 $7,828,696 +$1,536 +0.02% 31 Jul 2015 10-Q/A 19 Jan 2016 2016 Q1
Q1 2015 $7,777,126 -$1,165,258 -13% 30 Apr 2015 10-K 27 Jul 2017 2017 FY
Q4 2014 $6,247,959 +$1,064,912 +21% 31 Jan 2015 10-Q 13 Mar 2015 2015 Q3
Q3 2014 $6,382,227 +$2,778,925 +77% 31 Oct 2014 10-Q 15 Dec 2014 2015 Q2
Q2 2014 $7,827,160 +$5,927,124 +312% 31 Jul 2014 10-Q 15 Sep 2014 2015 Q1
Q1 2014 $8,942,384 +$10,443,840 30 Apr 2014 10-K 29 Jul 2016 2016 FY
Q4 2013 $5,183,047 +$7,212,376 31 Jan 2014 10-Q 17 Mar 2014 2014 Q3
Q3 2013 $3,603,302 +$5,657,572 31 Oct 2013 10-Q 16 Dec 2013 2014 Q2
Q2 2013 $1,900,036 +$4,272,626 31 Jul 2013 10-Q 16 Sep 2013 2014 Q1
Q1 2013 $1,501,456 +$778,394 +34% 30 Apr 2013 10-K 29 Jul 2016 2016 FY
Q4 2012 $2,029,329 +$218,460 +9.7% 31 Jan 2013 10-Q 26 Mar 2013 2013 Q3
Q3 2012 $2,054,270 +$321,216 +14% 31 Oct 2012 10-Q 26 Dec 2012 2013 Q2
Q2 2012 $2,372,590 +$33,509 +1.4% 31 Jul 2012 10-Q 19 Sep 2012 2013 Q1
Q1 2012 $2,279,850 +$449,443 +16% 30 Apr 2012 10-K/A 19 Jan 2016 2015 FY
Q4 2011 $2,247,789 31 Jan 2012 10-Q 21 Mar 2012 2012 Q3
Q3 2011 $2,375,486 31 Oct 2011 10-Q 15 Dec 2011 2012 Q2
Q2 2011 $2,406,099 31 Jul 2011 10-Q/A 20 Sep 2011 2012 Q1
Q1 2011 $2,729,293 -$278,148 -11% 30 Apr 2011 10-K 29 Jul 2013 2013 FY
Q1 2010 $2,451,145 30 Apr 2010 10-K 14 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.